化合物 MK-2206 dihydrochloride|T1952|TargetMol

MK-2206 dihydrochloride
1032350-13-2

￥298 1mg 起订

￥428 2mg 起订

￥689 5mg 起订

上海更新日期：2024-09-23

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 化合物 MK-2206 dihydrochloride

英文名称：: MK-2206 dihydrochloride

CAS号：: 1032350-13-2

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.91%

产品类别：: 抑制剂

货号：: T1952

Product Introduction

Bioactivity

名称	MK-2206 dihydrochloride
描述	MK-2206 dihydrochloride (MK-2206 2HCl) is a variant Akt inhibitor that inhibits Akt1, Akt2, and Akt3 (IC50=8/12/65 nM) with orally active, highly potent and selective potency. MK-2206 dihydrochloride exhibits antitumor activity.
细胞实验	Cells were seeded at a density of 2 to 3 × 103 per well in 96-well plates. Twenty-four hours after plating, varying concentrations of the drug, either as a single agent or in combination, were added to the wells. Cell proliferation was determined by using the CellTiter-Glo assay at 72 or 96 hours after dosing. The nature of the drug interaction was evaluated by using the combination index (CI) according to the method of Chou and Talalay. A commercial software package was obtained from Calcusyn. In combination with docetaxel, we tested three treatment sequences: (a) MK-2206 followed by docetaxel—cells were exposed to MK-2206 for 24 hours, and then after washout of MK-2206, cells were treated with docetaxel for an additional 72 hours; (b) docetaxel followed by MK-2206—cells were exposed to docetaxel for 24 hours, and then after washout of docetaxel, cells were treated with MK-2206 for an additional 72 hours; and (c) concurrent treatment—cells were exposed to both MK-2206 and docetaxel for 72 hours [2].
动物实验	When the mean tumor size reached 0.13 cm3 for the SK-OV-3 or 0.2 cm3 for the NCI-H292, HCC70, PC-3, and NCI-H460 models, the mice were randomized into control and treatment groups with approximately equivalent ranges of tumor volume between groups (n = 5 animals per group). The following vehicles were used to dose the compounds: 30% Captisol (Cydex) for MK-2206; 0.5% methylcellulose + 0.1% Tween 80 for erlotinib; distilled water for lapatinib; 0.73% ethanol in saline for docetaxel; and saline for carboplatin and gemcitabine. The control group received vehicle only. Tumor volume was measured with calipers twice a week. Animal body weight and physical signs were monitored during the experiments. Tumor volume was calculated, taking length to be the longest diameter across the tumor and width to be the perpendicular diameter, by using the following formula: (length × width)2 × 0.5. Relative tumor volume was assessed by dividing the tumor volume on different observation days with the starting tumor volume. Statistical significance was evaluated by using the two-way repeated ANOVA test followed by Dunnett's test or an unpaired t-test [2].
体外活性	方法：14 种肿瘤细胞用 MK-2206 dihydrochloride 处理 72 h，使用 CellTiter-Glo assay 检测细胞活力。结果：MK-2206 dihydrochloride 抑制肿瘤细胞生长，IC50 在 0.1-28.6 μmol/L之间。[1] 方法：人鼻咽癌细胞系 CNE-2、HONE-1 用 MK-2206 dihydrochloride (0.625-10 μM) 处理 24-48 h，使用 Flow Cytometry 方法检测细胞周期情况。结果：MK-2206 dihydrochloride 导致 G0/G1 期细胞百分比的剂量依赖性增加和 S 期细胞数量的减少。MK-2206 dihydrochloride 诱导细胞周期停滞于 G1 期。[2]
体内活性	方法：为检测体内抗肿瘤活性，将 MK-2206 dihydrochloride (120 mg/kg 每周三次或 360 mg/kg 每周一次，30% Captisol) 和 erlotinib (50 mg/kg 每周五次，0.5% methylcellulose + 0.1% Tween 80) 口服给药给携带人肺癌肿瘤 NCI-H292 的 CD1 小鼠，持续两周。结果：每周三次的 MK-2206 单药治疗无效，每周一次的方案仅介导中等的抗肿瘤疗效。尽管 erlotinib 单独介导了显著的肿瘤生长抑制，但与 MK-2206 的联合治疗显著增强了其抗肿瘤疗效，包括肿瘤消退。[1] 方法：为检测体内抗肿瘤活性，将 MK-2206 dihydrochloride (120 mg/kg in 30% captisol) 灌胃给药给携带人子宫内膜癌肿瘤的 NSG 小鼠，每周两次，持续三周。结果：MK-2206 dihydrochloride 治疗使 3 种不同类型和等级的 PDX 肿瘤的生长都受到显著抑制。[3]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 7.5 mg/mL (15.61 mM) 10% DMSO+90% Saline : 0.75 mg/mL (1.56 mM), Working solution is recommended to be prepared and used immediately.
关键字	Apoptosis \| mutant \| Inhibitor \| MK 2206 \| cancer \| inhibit \| MK-2206 (2HCl) \| MK2206 dihydrochloride \| PIK3CA \| selective \| MK-2206 Dihydrochloride \| Autophagy \| Protein kinase B \| Akt \| loss \| PKB \| PTEN \| sensitive \| oral \| MK 2206 Dihydrochloride \| breast \| MK-2206 \| MK2206 \| MK 2206 dihydrochloride \| MK2206 Dihydrochloride
相关产品	Guanidine hydrochloride \| Naringin \| Taurine \| Gefitinib \| Hydroxychloroquine \| 5-Fluorouracil \| Curcumin \| Stavudine \| Tributyrin \| L-Ascorbic acid \| Paeonol \| Sodium 4-phenylbutyrate
相关库	抑制剂库 \| 抗癌活性化合物库 \| 经典已知活性库 \| 已知活性化合物库 \| 激酶抑制剂库 \| 抗衰老化合物库 \| 高选择性抑制剂库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

MK-2206 2HCl|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子